Insight

Osimertinib could change the standard of care for EGFR-mutant NSCLC

Photo taken from fiercepharma.com

Jul 12, 2024, 23:07

Osimertinib could change the standard of care for EGFR-mutant NSCLC

Iván R. González, Medical Oncologist at Ángeles Puebla Hospital, shared on X:

“Osimertinib could change the standard of care for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC).

The LAURA trial showed that osimertinib improves progression-free survival (PFS) in patients with unresectable NSCLC, reducing the risk of progression or death by 84% vs. placebo.

The median PFS was 39.1 months vs. 5.6 months.

The most common adverse events were radiation pneumonitis, diarrhea, and rash.”

For Patients With EGFR-Mutated Lung Cancer, Osimertinib Trial Might Change Guidelines

Source: Iván R. González/X

Ángeles Puebla Hospital cancer Comprehensive Oncology Center EGFR-mutant NSCLC Iván R. González LAURA trial non small cell lung cancer OncoDaily Oncology osimertinib progression-free survival unresectable NSCLC

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Special Coverage